Nuvation Bio (NUVB) to Release Earnings on Thursday

Nuvation Bio (NYSE:NUVB) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter.

Nuvation Bio Stock Performance

Shares of NUVB opened at $1.97 on Thursday. The business has a 50-day moving average of $2.53 and a 200 day moving average of $2.63. Nuvation Bio has a fifty-two week low of $1.67 and a fifty-two week high of $4.16. The firm has a market cap of $663.04 million, a P/E ratio of -0.91 and a beta of 1.45.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective (up previously from $6.00) on shares of Nuvation Bio in a report on Tuesday, January 7th. Wedbush reissued an “outperform” rating and set a $5.00 price objective on shares of Nuvation Bio in a report on Monday, January 6th. Finally, HC Wainwright boosted their price objective on Nuvation Bio from $10.00 to $11.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $8.20.

About Nuvation Bio

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.